N Singh1, L Kumar, R Meena, T Velpandian. 1. Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
Abstract
PURPOSE: Imatinib mesylate is used as first line therapy in the treatment of chronic myeloid leukaemia. This study was designed to study the correlation of plasma levels of imatinib with response to the therapy. METHODS: A total of 40 chronic myeloid leukaemia patients in the chronic phase of the disease were recruited and placed into two groups of 20 patients: imatinib responders and imatinib non-responders, respectively. Each blood sample was taken 24 h after and immediately prior to taking a 400 mg oral dose of imatinib. Drug levels were detected by high-performance liquid chromatography. RESULTS: The mean plasma imatinib levels in the imatinib non-responders were significantly lower than those in the imatinib responders (0.70 vs. 2.34 microM, respectively; p = 0.002). CONCLUSIONS: Plasma levels of imatinib were correlated with response to the therapy, so routine monitoring of the therapeutic levels of the drug should be carried out specifically in treatment-resistant cases for determining dose escalation.
PURPOSE:Imatinib mesylate is used as first line therapy in the treatment of chronic myeloid leukaemia. This study was designed to study the correlation of plasma levels of imatinib with response to the therapy. METHODS: A total of 40 chronic myeloid leukaemiapatients in the chronic phase of the disease were recruited and placed into two groups of 20 patients: imatinib responders and imatinib non-responders, respectively. Each blood sample was taken 24 h after and immediately prior to taking a 400 mg oral dose of imatinib. Drug levels were detected by high-performance liquid chromatography. RESULTS: The mean plasma imatinib levels in the imatinib non-responders were significantly lower than those in the imatinib responders (0.70 vs. 2.34 microM, respectively; p = 0.002). CONCLUSIONS: Plasma levels of imatinib were correlated with response to the therapy, so routine monitoring of the therapeutic levels of the drug should be carried out specifically in treatment-resistant cases for determining dose escalation.
Authors: Yuan Wei; Mats Hardling; Bob Olsson; Rahil Hezaveh; Anne Ricksten; Dick Stockelberg; Hans Wadenvik Journal: Ann Hematol Date: 2006-09-28 Impact factor: 3.673
Authors: Philipp le Coutre; Karl-Anton Kreuzer; Stefan Pursche; Malte v Bonin; Traugott Leopold; Gökben Baskaynak; Bernd Dörken; Gerhard Ehninger; Oliver Ottmann; Andreas Jenke; Martin Bornhäuser; Eberhard Schleyer Journal: Cancer Chemother Pharmacol Date: 2003-12-05 Impact factor: 3.333
Authors: Jan H Beumer; Venkateswaran C Pillai; Robert A Parise; Susan M Christner; Brian F Kiesel; Michelle A Rudek; Raman Venkataramanan Journal: Br J Clin Pharmacol Date: 2015-09-19 Impact factor: 4.335
Authors: Nienke A G Lankheet; Ingrid M E Desar; Sasja F Mulder; David M Burger; Dinemarie M Kweekel; Carla M L van Herpen; Winette T A van der Graaf; Nielka P van Erp Journal: Br J Clin Pharmacol Date: 2017-07-04 Impact factor: 4.335
Authors: Edgar Faber; David Friedecký; Katerina Micová; Martina Divoká; Beata Katrincsáková; Sárka Rozmanová; Marie Jarosová; Karel Indrák; Tomás Adam Journal: Int J Hematol Date: 2010-05-01 Impact factor: 2.490
Authors: Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447